drugset / Trial / NCT04509882

Bear Bile Pill as add-on the Treatment of MDD

NCT04509882 ↗

Phase 2 Unknown 120 enrolled Shanghai Mental Health Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single-center, double blind, randomized, placebo-controlled, parallel group study of bear bile pill, as add-on therapy in MDD patients conducted in Shang Hai Mental Health Center. The purpose of this study is to determine the efficacy and safety of bear bile pill in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy. Following a screening period, subjects who meet the entry criteria will be randomized to treated with either placebo or 450mg bear bile pill three times daily for 8 weeks.

Timeline

Start
2020-10-30
Primary completion
2022-03-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject bear bile pill Unknown 450 mg Oral